{
}
The global diabetic retinopathy devices market, valued at USD 12.47 billion in 2022, is projected to grow at a robust CAGR of around 30% through 2030, driven by rising diabetes cases and an aging population. Non-proliferative diabetic retinopathy is expected to dominate, while North America will lead regionally, with significant contributions from the APAC region due to its large diabetic population. Key players include F. Hoffmann-La Roche, Novartis, and Regeneron, focusing on innovative treatments and technologies.
The difelikephalin drug market, valued at $XX billion in 2022, is projected to grow at a CAGR of 6.5% from 2023 to 2030, driven by increased product launches and rising cases of pruritus linked to chronic kidney disease. North America is expected to dominate the market, with major players including F. Hoffmann-La Roche Ltd and Regeneron Pharmaceuticals Inc. The online distribution segment is anticipated to experience significant growth due to the rise of digital media and social media marketing.
Amgen is set to launch its Eylea biosimilar, Pavblu, after a court ruling lifted a temporary injunction that had blocked its introduction. Despite Regeneron's claims of patent infringement and plans to continue legal battles, analysts suggest Amgen's move may be a tactic to prompt a settlement. The legal dispute intensified after a district court denied Regeneron's request for a preliminary injunction, allowing Amgen to proceed with its launch "at risk."
The drug and biotech sector is experiencing a strong earnings season, highlighted by Johnson & Johnson's recent performance, which exceeded estimates and led to an upward revision of revenue expectations. Five large drug companies—Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals, and Biogen—are anticipated to outperform in their upcoming quarterly results, with Novo Nordisk showing a positive Earnings ESP of +1.02% and a Zacks Rank #3. Overall, the Medical sector is projected to see a 6.4% rise in fourth-quarter earnings and an 8.5% increase in revenues.
Regeneron Pharmaceuticals is set to report its Q3 earnings on October 31, with analysts expecting a profit of $9.97 per share, a slight decline from the previous year. The stock has risen 14.8% year-to-date, though it lags behind the S&P 500's 22.5% gain. Despite a recent downgrade, the consensus remains bullish, with 18 out of 25 analysts recommending a "Strong Buy."
GSK announced positive results from two Phase 3 trials of its antibody drug depemokimab for chronic rhinosinusitis with nasal polyps (CRSwNP), showing significant suppression of nasal polyp growth and improved nasal obstruction compared to placebo. The drug, which targets IL-5, is also being studied for asthma and other inflammatory diseases, with potential peak annual sales exceeding £3 billion if approved. Detailed trial results will be presented at an upcoming scientific congress.
Regeneron Pharmaceuticals, Inc.
Companies
| Symbol | REGN |
| Name | Regeneron Pharmaceuticals, Inc. |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Market | NASDAQ Global Select |
| Country | United States |
| State | NY |
| City | Tarrytown |
| Zipcode | 10591-6707 |
| Website | http://www.regeneron.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
diabetic retinopathy market poised for significant growth driven by rising diabetes cases
Indian Rupee
Pakistani Rupee
Chinese Yuan
United States Dollar
Regeneron Pharmaceuticals, Inc.
Sanofi
Coherus BioSciences, Inc.
Novartis AG
Bayer AG
Kodiak Sciences Inc.
HANLIM PHARM.CO.LTD
Intas Pharmaceuticals Ltd.
SUN Pharmaceutical Industries Ltd.
F. Hoffmann-La Roche Ltd.
PAK
CHN
IND
Bayer
Regeneron Pharmaceuticals
Sun Yat-Sen
Novartis
F. Hoffmann-La Roche
Show more
14:04 26.10.2024
difelikephalin drug market poised for growth driven by chronic kidney disease treatments
United States Dollar
Vifor Pharma Management Ltd
Amgen Inc.
Biogen Inc.
Entia
Benevolent IA
IDEXX
F. Hoffmann-La Roche Ltd.
Regeneron Pharmaceuticals, Inc.
AstraZeneca PLC
VENOSTENT, INC
USA
CHN
Show more
16:20 25.10.2024
Amgen prepares to launch Eylea biosimilar amid ongoing legal battles
United States Dollar
Formycon AG
Biogen Inc.
Regeneron Pharmaceuticals, Inc.
Amgen Inc.
Sandoz Group AG
Biocon Biologics
USA
Brian Skorney
Christopher Raymond
Show more
16:20 23.10.2024
large drug stocks poised to exceed q3 earnings expectations
Novartis AG
Novo Nordisk A/S
Biogen Inc.
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
DNK
Regeneron Pharmaceuticals
Novo Nordisk
Biogen
Novartis
Pfizer
Show more
14:31 22.10.2024
regeneron pharmaceuticals set to report q3 earnings with mixed analyst expectations
United States Dollar
Healthcare Select Sector SPDR Fund
Regeneron Pharmaceuticals, Inc.
USA
Kritika Sarmah
09:00 17.10.2024
GSK reports positive Phase 3 results for chronic nasal condition drug
British Pound Sterling
Sanofi
Regeneron Pharmaceuticals, Inc.
Glaxosmithkline Export Ltd.
GBR
USA
Kaivan Khavandi
Show more
14:01 14.10.2024
Trending
Subcategory
Corporate News
Startups & Entrepreneurship
Industry Trends
Global Trade Developments
Stock Market Updates
Industry Mergers & Acquisitions
Private Equity Deals
Government Economic Policies
Supply Chain Management
Fintech Startups
Venture Capital Investments
Retail and Consumer Goods
Inflation and Monetary Impact
Workplace Trends
Energy Sector Developments
Finance Mergers & Acquisitions
Central Bank Actions
CEO Changes
Emerging Startups
Crypto Policies and Governance
Countries:
Companies:
Apple Inc.
NIO Inc.
Nikkei 225
Google Inc.
Nintendo Co., Ltd.
Grab2Go AS
OLA ELECTRIC MOBILITY LTD
Eurasia Groupe SA
British International Investment plc
XPeng Inc.
Li Auto Inc.
Morgan Stanley
Taiwan Semiconductor Manufacturing Company Limited
VFS Global AG
LARGAN Precision Co.,Ltd
S&P/ASX 200
HANG SENG BANK
Delhivery Limited
Ecom Express Ltd.
Arazul Sequoia Capital FIM C Priv
Currencies:
United States Dollar
Indian Rupee
Euro
Chinese Yuan
Japanese Yen
United Arab Emirates Dirham
New Taiwan Dollar
Indonesian Rupiah
Saudi Riyal
Offshore Chinese Yuan
Hong Kong Dollar
Malaysian Ringgit
Filipino Peso
West African CFA Franc
South Korean Won
Thai Baht
Mexican Peso
Croatian Kuna
Bahraini Dinar
Egyptian Pound
People: